^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

    Excerpt:
    ...- Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER> 10% tumor cell positive is defined as ER positive, PR> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH detection,...
    Trial ID:
    BCTOP-L-M04
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Fulvestrant combined with apatinib in patients with hormone receptor-positive, HER-2 negative advanced breast cancer: a phase 2, single-arm, prospective study

    Excerpt:
    ...Histologically diagnosis of hormone receptor positive (ER and/or PR+), HER2 negative breast cancer(ER positive: immunohistochemistry (IHC) ＞1% tumor cell staining; PR positive: immunohistochemistry (IHC) ＞1% tumor cell staining; HER-2 negative: immunohistochemistry 0, 1+, or 2+ while FISH/CISH negative); 3. ...
    Trial ID:
    ChiCTR1900021617
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review

    Published date:
    06/18/2021
    Excerpt:
    Here, we report the case of a 34-year-old woman with hormone receptor-positive and HER2-negative ABC who was successfully treated with low-dose Apatinib.
    DOI:
    10.1097/CAD.0000000000001102